102297-62-1Relevant articles and documents
TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
-
Page/Page column 75-76, (2012/09/10)
The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthama, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. (I)
Chalcone derivatives and drugs containing the same
-
, (2008/06/13)
PCT No. PCT/JP97/01652 Sec. 371 Date Nov. 17, 1998 Sec. 102(e) Date Nov. 17, 1998 PCT Filed May 16, 1997 PCT Pub. No. WO97/44306 PCT Pub. Date Nov. 27, 1997This invention relates to chalcone derivatives represented by the following formula (1): wherein A represents a phenyl group, a quinolyl group or the like, W represents a vinylene group or the like, and R1 to R5 each independently represent a carboxyl, cyano, alkyloxycarbonyl or like group, or salts of the chalcone derivatives, and also to drugs containing them as effective ingredients. These compounds have excellent cys-LT receptor antagonism, and are useful as antiallergic agents or the like.
Synthesis of (+/-)-Sydonic Acid
Murali, D.,Rao, G. S. Krishna
, p. 156 - 157 (2007/10/02)
A two-step synthesis of sydonic acid (1) makes use of the phenolic acetylbenzoic acid (4) obtained by the regio-selective oxidation of the known 2-acetoxy-4-methylacetophenone (3) by benzyltriethylammonium permanganate (BTAP).Similar BTAP oxidation of the
